Stock market analyst Hitesh Chotalia has maintained 'buy' rating on Glenmark Pharmaceutical Ltd stock to achieve a short term target of Rs 315.

According to analyst, the investors can buy the stock with stop loss of Rs 270,

The stock of the company, on July 08, closed at Rs 279.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 303.80 and a low of Rs 210.50 on BSE.

Current EPS & P/E ratio stood at 12.27 and 23.12 respectively.

Glenmark Pharmaceuticals, which had revenues of more than Rs 1,000 crore during the last fiscal, has set its eyes on the US oral contraceptives (hormones) section.

The company's arm Glenmark Generics, which looks after overseas business, unveiled an oral contraceptive called 'Heather' in July, and has ten more products under way.

On July 02, Glenmark Generics, USA (GGI), a division of Glenmark Generics (GGL), has got ANDA nod from the USFDA for Adapalene Gel, 0.1%.

The company will shortly start marketing and distribution of Adapalene Gel in the United States.